Overview

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

Status:
Not yet recruiting
Trial end date:
2023-09-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics (PK), safety, and tolerability of JDQ443 in participants with varying degrees of hepatic impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals